Resource details
Dravet syndrome (DS) is an early onset refractory epilepsy typically caused by de novo heterozygous variants in the SCN1A gene encoding the α-subunit of the neuronal sodium voltage-gated channel Na v 1.1 (Brunklaus and Zuberi, 2014) . Characteristic clinical features are agerelated progression of seizures, cognitive decline and movement disorders such as ataxia. Seizures, beginning within the first year of life, are often pharmacoresistant and the mortality rate is high (Gataullina and Dulac, 2018; Miller and de Menezes, 2007) . The distinct neurodevelopmental features in DS are presumably caused by the disruption of molecular pathways in Na v 1.1 haploinsufficient cells resulting in perturbed neuronal functions. Here, we report on the generation and characterization of iPSC lines derived from three individuals with DS carrying distinct germ line mutation in the SCN1A gene [c.5502-5509dupGCTTGAAC (p.Phe1837fs); c.2965G > C (p.Ala989Phe); c.651C > G (p.Thr217Arg), respectively]. The affected individuals presented with generalized febrile seizures within the first ten months of life and variable degree of psychomotor delay from the second year of life.
Primary fibroblasts of the three DS patients were transduced using the Sendai virus reprogramming system. One clonal iPSC line from each patient (DD1C, DD4A and DD5A) was expanded as monolayer in tight colonies and showed typical iPSC morphology with large nucleus-tocytoplasm ratio, prominent nuclei and defined luminescent borders as seen by Bright-field microscopy ( Fig. 1A ; size bar: 100 μm) Tables 1-3. Endogenous expression of the pluripotency markers NANOG, SOX2, TRA-1-60 and SSEA4 was demonstrated by flow cytometry (Fig. 1B ) and immunocytochemistry (Fig. 1C , size bar: 100 μm), respectively, in all three iPSC lines. Cell authentication using a set of 16 polymorphic short tandem repeats (STRs) confirmed that the established iPSC lines matched the donor fibroblasts. Additionally, each of the three DS patient derived iPSC lines DD1C, DD4A and DD5A retained the pathogenic SCN1A gene variant [c.5502-5509dupGCTTGAAC (DD1C); c.2965G > C (DD4A); c.651C > G (DD5A)] of the donor as confirmed by Sanger sequencing ( Fig. 1D ; Supplementary Fig. S1 ).
Analysis of the three iPSC lines using scorecards showed pluripotency marker expression corresponding to an undifferentiated state using a reference set of 23 pluripotent stem cell lines ( Fig. 1E ) (Gataullina and Dulac, 2018) . The differentiation potential of the three iPSC lines DD1C, DD4A and DD5A was assessed by embryoid body (EB) formation. Expression of specific markers for ectoderm, mesoderm and endoderm using scorecard analysis confirmed that the iPSC lines are J. Schuster, et al. Stem Cell Research 39 (2019) 101523 capable of differentiating into the three germ layers ( Fig. 1E ). Moreover, the three DS iPSC lines DD1C, DD4A and DD5A were devoid of Sendai reprogramming vector confirmed by RT/PCR ( Fig. 1D ) and all three iPSC lines tested free of Mycoplasma infection using MycoAlert™ Mycoplasma detection kit (Supplementary File 1). Genomic integrity was investigated by karyotyping and no acquired chromosomal aberration was detected in any of the iPSC lines ( Fig. 1G ).
The DS patient derived iPSC lines offer a useful resource to study the neuropathophysiology caused by Na v 1.1 haploinsufficiency and allow for drug screening with the goal to develop improved treatment options for this devastating disease.
Materials and methods

Culture conditions
Fibroblasts were cultured in DMEM, Sigma, cat no: D5796, 10% fetal bovine serum, ThermoFisher Scientific, cat no: 10500056, 2 mM GlutaMAX™, ThermoFisher Scientific, cat no: 35050038, 1% penicillin/ streptomycin, ThermoFisher Scientific, cat no: 15140122 in a humidified atmosphere with 5% CO 2 at 37°C and passaged using TrypLE™ Express, ThermoFisher Scientific, cat no: 12604039, and Defined Trypsin Inhibitor, ThermoFisher Scientific, cat no: R007100 at a ratio of 1:5 when 60% confluent.
IPS cells were cultured (5%CO 2 , 37°C) in Essential-8™ medium, ThermoFisher Scientific, cat no: A1517001, on Vitronectin-XF™, Stem Cell Technologies, cat no: 07180, coated plates and passaged with Gentle Cell Dissociation Reagent, Stem Cell Technologies, cat no: 07174 every 4-6 days at a ratio of 1:4-1:10. After passage P25, iPSC lines were adapted to culture on human Laminin-521, Biolamina, cat no: LN-521, and passaged using TrypLE™ Express and Defined Trypsin Inhibitor at a ratio of 1:6-1:10 when 60-80% confluent.
For embryonic body formation, iPSC were dissociated with Accutase, Sigma cat no: A6964, and approximately 1,5 × 10 6 iPSCs were seeded into an AggreWell™400 plate, Stem Cell Technologies, cat no: 34421, in AggreWell™ medium, Stem Cell Technologies, cat no: 05893, supplemented with 10 μM Rho-kinase inhibitor Y27632, Stem Cell Technologies, cat no: 72304 according to protocol. Next day, embryoid bodies were transferred to non-adherent culture plates and further differentiated for four weeks. Medium was changed 2-3 times/ week (week 1, AggreWell™ medium, from week 2: Knockout™ DMEM, ThermoFisher Scientific, cat no: 10829018, 15% KnockOut™ Serum Replacement, ThermoFisher Scientific, cat no: A3181501, 1% fetal bovine serum, 2 mM GlutaMAX™, 1% non-essential amino acids, 1% penicillin/streptomycin).
Reprogramming
Fibroblasts were reprogrammed using CytoTune™-iPS 2.0 Sendai Reprogramming Kit, ThermoFisher Scientific, cat no: A16517, expressing the four Yamanaka factors hKLF4, hc-MYC, hSOX2, hOCT3/4 according to manufacturer's instructions. iPSC colonies were manually picked after 21-28 days for passage 1 to Vitronectin™-XL coated dishes and clonally expanded (see Culture conditions). Established iPSC lines were adapted to culture on LN-521 (see Culture Conditions) past passage P25.
Cell authentication
Cell authentication on DNA (NucleoSpin® tissue kit, Macherey-Nagel, cat no:740952.250) from fibroblasts and iPSC lines was performed at Eurofins Genomics, Germany using AmpFLSTR™ Identifiler™ PCR Amplification Kit, ThermoFisher Scientific, cat no: 4322288. 
Genome stability
Genome stability was analyzed by karyotyping of individual metaphases and chromosomes were stained with Giemsa (G) solution at the Department of Clinical Genetics, Uppsala University Hospital. Analysis of G-banded chromosomes on 20 fixed metaphases was performed using the Metafer slide scanning platform and Ikaros software, MetaSystems.
RT-PCR
RNA was isolated using miRNeasy micro kit, Qiagen, cat no: 217084. cDNA was synthesized using High Capacity cDNA Synthesis kit, ThermoFisher Scientific, cat no: 4368814 from 1 μg of total RNA. Detection of Sendai virus was performed by PCR on a "MyCycler" thermal cycler, BIORAD, by a total of 35 cycles (95°C -30 s, 55°C -1 min, 72°C -1 min) with 1/10 of the cDNA reaction with primers SeV-F and SeV-R. GAPDH was used as positive control. RNA isolated from cells set aside after Sendai Virus infection (day 3) were used as positive control. Samples were run without template as negative control.
PCR products (expected sizes SeV: 195 bp (SeV), GAPDH: 325 bp) were visualized by 1% agarose gel electrophoresis. Ladder: GeneRuler 100 bp DNA ladder, ThermoFisher Scientific, cat no: SM0243.
Immunofluorescence
Cells were fixed in 4% ice-cold formaldehyde for 5 min at room temperature (RT) and pre-incubated in 1xPBS, 1%BSA, 0,3% TritonX100 at RT. Primary antibodies (mouse anti-NANOG, rabbit anti-SOX2) were diluted in pre-incubation buffer and incubated at 4°C overnight. Secondary antibodies (donkey anti-mouse AF647, donkey anti-goat AF488) diluted in pre-incubation buffer were incubated at room temperature for 60 min. Nuclear marker, DAPI (1 μg/ml), Sigma cat no: D8417 was incubated for 10 min at room temperature and specimens were mounted onto microscope slides using CFM-3 mounting medium, Citifluor. Specimens were imaged using an AxioImager (Zeiss).
Flow cytometry
iPSCs were harvested with Accutase, Sigma cat no: A6964 and washed in 1%BSA/1xPBS. Primary antibodies (mouse-IgG anti-SSEA4, mouse-IgM anti TRA-1-60) diluted in 1%BSA/1xPBS were incubated at room temperature for 30 min. Secondary antibodies (goat anti-mouse IgM AF488, goat anti-mouse IgG AF555) diluted in 1%BSA/1xPBS were incubated for 20 min at room temperature. Cells were analyzed on a LSR-FORTESSA (BD) using FACSDiva™ software (BD).
Scorecard assay
RNA was extracted (see RT-PCR) and quality was assessed by Agilent BioAnalyzer. Samples were run on TaqMan® hPSC Scorecard™ Panel, ThermoFisher Scientific, cat no: A15872/A15870 following manufacturer's protocol (Fergus et al., 2016) . Scorecards were analyzed with company's software at https://apps.thermofisher.com/ hPSCscorecard/home.htm.
Mycoplasma
Presence of mycoplasma in iPSC lines was assessed on cell culture supernatants using MycoAlert™ Mycoplasma Detection kit, Lonza, cat no: LT07-318.
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